Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-282Price:$104.49
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,475Price:$103.69
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,243Price:$103.10
-
Apr 15, 2024 (filed on Apr 16, 2024)Insider Name:Hoge StephenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,000Price:$105.02
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-389Price:$109.36
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-748Price:$108.56
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7,512Price:$107.31
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,351Price:$106.59
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Mock James MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-705Price:$101.93
-
Apr 05, 2024 (filed on Apr 09, 2024)Insider Name:Mock James MOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,453Price:--
Filings by filing date
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-282Price:$104.49
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,475Price:$103.69
-
Apr 17, 2024 (filed on Apr 19, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,243Price:$103.10
-
Apr 15, 2024 (filed on Apr 16, 2024)Insider Name:Hoge StephenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,000Price:$105.02
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-389Price:$109.36
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-748Price:$108.56
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7,512Price:$107.31
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Afeyan NoubarOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,351Price:$106.59
-
Apr 05, 2024 (filed on Apr 09, 2024)Insider Name:Mock James MOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,453Price:--
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Mock James MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-705Price:$101.93
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 325 BINNEY STREET Cambridge MA 02142 |
Tel: | N/A |
Website: | https://www.modernatx.com |
IR: | See website |
Key People | ||
Stephen Hoge President | Stephane Bancel Chief Executive Officer, Director | James M. Mock Chief Financial Officer |
Jerh Collins Chief Technical Operations and Quality Officer | Tracey Franklin Chief Human Resources Officer | Brad Miller Chief Information Officer |
Kate Cronin Chief Brand Officer | Shannon Thyme Klinger Corporate Secretary, Chief Legal Officer |
Business Overview |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Moderna Inc revenues decreased 64% to $6.85B. Net loss totaled $4.71B vs. income of $8.36B. Revenues reflect Europe segment decrease of 80% to $1.36B, Rest of the World segment decrease of 51% to $3.6B. Net loss reflects Research and development increase of 46% to $4.69B (expense), General and administrative increase of 38% to $1.44B (expense). |
Employees: | 5,600 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $30,799M as of Dec 31, 2023 |
Annual revenue (TTM): | $6,848M as of Dec 31, 2023 |
EBITDA (TTM): | -$3,617M as of Dec 31, 2023 |
Net annual income (TTM): | -$4,714M as of Dec 31, 2023 |
Free cash flow (TTM): | -$3,825M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 382,879,612 as of Mar 7, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |